Archives of Pharmacal Research

, Volume 37, Issue 1, pp 16–23 | Cite as

Extracellular stability of nanoparticulate drug carriers

  • Karen C. Liu
  • Yoon Yeo


Nanoparticulate (NP) drug carrier systems are attractive vehicles for selective drug delivery to solid tumors. Ideally, NPs should evade clearance by the reticuloendothelial system while maintaining the ability to interact with tumor cells and facilitate cellular uptake. Great effort has been made to fulfill these design criteria, yielding various types of functionalized NPs. Another important consideration in NP design is the physical and functional stability during circulation, which, if ignored, can significantly undermine the promise of intelligently designed NP drug carriers. This commentary reviews several NP examples with stability issues and their consequences, ending in a discussion of experimental methods for reliable prediction of NP stability.


Nanomedicine Nanoparticles Drug delivery Stability Sensitivity 



This work was supported by NSF DMR-1056997, a Grant from the Lilly Endowment, Inc. to College of Pharmacy, Purdue University, and Intramural Research Program (Global RNAi Carrier Initiative) of Korea Institute of Science and Technology. This study was also partly supported by the NIH/NCRR-Indiana Clinical and Translational Sciences Institute Pre-doctoral Fellowship (TL1 RR025759, PI: A. Shekhar) to KCL.


  1. Amoozgar, Z., J. Park, Q. Lin, and Y. Yeo. 2012. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Molecular Pharmaceutics 9: 1262–1270.PubMedCentralPubMedGoogle Scholar
  2. Bajaj, G., M.R. Kim, S.I. Mohammed, and Y. Yeo. 2012. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors. Journal of Controlled Release 158: 386–392.PubMedCentralPubMedCrossRefGoogle Scholar
  3. Burt, H.M., X. Zhang, P. Toleikis, L. Embree, and W.L. Hunter. 1999. Development of copolymers of poly(d, l-lactide) and methoxypolyethylene glycol as micellar carriers of paclitaxel. Colloids and Surfaces B 16: 161–171.CrossRefGoogle Scholar
  4. Chen, H., S. Kim, W. He, H. Wang, P.S. Low, K. Park, and J.-X. Cheng. 2008a. Fast release of lipophilic agents from circulating PEG-PDLLA micelles revealed by in vivo Förster resonance energy transfer imaging. Langmuir 24: 5213–5217.PubMedCrossRefGoogle Scholar
  5. Chen, H., S. Kim, L. Li, S. Wang, K. Park, and J.-X. Cheng. 2008b. Release of hydrophobic molecules from polymer micelles into cell membranes revealed by Forster resonance energy transfer imaging. Proceedings of the National Academy of Sciences 105: 6596–6601.CrossRefGoogle Scholar
  6. Cho, E.J., H. Holback, K.C. Liu, S.A. Abouelmagd, J. Park, and Y. Yeo. 2013. Nanoparticle characterization: State of the art, challenges, and emerging technologies. Molecular Pharmaceutics 10: 2093–2110.PubMedCrossRefGoogle Scholar
  7. De Smet, M., E. Heijman, S. Langereis, N.M. Hijnen, and H. Grüll. 2011. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: An in vivo proof-of-concept study. Journal of Controlled Release 150: 102–110.PubMedCrossRefGoogle Scholar
  8. Desai, N. 2008. Nab technology: A drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting drug delivery report, winter 2007/2008, 37–41.Google Scholar
  9. Ernsting, M.J., M. Murakami, E. Undzys, A. Aman, B. Press, and S.D. Li. 2012. A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, abraxane, in mouse tumor models with significant control of metastases. Journal of Controlled Release 162: 575–581.PubMedCrossRefGoogle Scholar
  10. Gerweck, L.E., and K. Seetharaman. 1996. Cellular pH gradient in tumor versus normal tissue: Potential exploitation for the treatment of cancer. Cancer Research 56: 1194–1198.PubMedGoogle Scholar
  11. Gregoriadis, G., and C. Davis. 1979. Stability of liposomes invivo and invitro is promoted by their cholesterol content and the presence of blood cells. Biochemical and Biophysical Research Communications 89: 1287–1293.PubMedCrossRefGoogle Scholar
  12. Gu, F., L. Zhang, B.A. Teply, N. Mann, A. Wang, A.F. Radovic-Moreno, R. Langer, and O.C. Farokhzad. 2008. From the cover: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proceedings of the National Academy of Sciences 105: 2586–2591.CrossRefGoogle Scholar
  13. Gullotti, E., and Y. Yeo. 2012. Beyond the imaging: Limitations of cellular uptake study in the evaluation of nanoparticles. Journal of Controlled Release 164: 170–176.PubMedCentralPubMedCrossRefGoogle Scholar
  14. Hamaguchi, T., K. Kato, H. Yasui, C. Morizane, M. Ikeda, H. Ueno, K. Muro, Y. Yamada, T. Okusaka, K. Shirao, Y. Shimada, H. Nakahama, and Y. Matsumura. 2007. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. British Journal of Cancer 97: 170–176.PubMedCentralPubMedCrossRefGoogle Scholar
  15. Harries, M., P. Ellis, and P. Harper. 2005. Nanoparticle albumin-bound paclitaxel for metastatic breast cancer. Journal of Clinical Oncology 23: 7768–7771.PubMedCrossRefGoogle Scholar
  16. Hatakeyama, H., H. Akita, and H. Harashima. 2011. A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: A strategy for overcoming the PEG dilemma. Advanced Drug Delivery Reviews 63: 152–160.PubMedCrossRefGoogle Scholar
  17. Kim, D., Z.G. Gao, E.S. Lee, and Y.H. Bae. 2009. In vivo evaluation of doxorubicin-loaded polymeric micelles targeting folate receptors and early endosomal pH in drug-resistant ovarian cancer. Molecular Pharmaceutics 6: 1353–1362.PubMedCentralPubMedCrossRefGoogle Scholar
  18. Kim, D., E.S. Lee, K.T. Oh, Z.G. Gao, and Y.H. Bae. 2008. Doxorubicin-loaded polymeric micelle overcomes multidrug resistance of cancer by double-targeting folate receptor and early endosomal pH. Small 4: 2043–2050.PubMedCentralPubMedCrossRefGoogle Scholar
  19. Kono, K., T. Ozawa, T. Yoshida, F. Ozaki, Y. Ishizaka, K. Maruyama, C. Kojima, A. Harada, and S. Aoshima. 2010. Highly temperature-sensitive liposomes based on a thermosensitive block copolymer for tumor-specific chemotherapy. Biomaterials 31: 7096–7105.PubMedCrossRefGoogle Scholar
  20. Kratz, F. 2008. Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. Journal of Controlled Release 132: 171–183.PubMedCrossRefGoogle Scholar
  21. Lee, E.S., K. Na, and Y.H. Bae. 2003a. Polymeric micelle for tumor pH and folate-mediated targeting. Journal of Controlled Release 91: 103–113.PubMedCrossRefGoogle Scholar
  22. Lee, E.S., H.J. Shin, K. Na, and Y.H. Bae. 2003b. Poly(l-histidine)–PEG block copolymer micelles and pH-induced destabilization. Journal of Controlled Release 90: 363–374.PubMedCrossRefGoogle Scholar
  23. Matsumura, Y., and H. Maeda. 1986. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research 46: 6387–6392.PubMedGoogle Scholar
  24. Miele, E., G.P. Spinelli, E. Miele, F. Tomao, and S. Tomao. 2009. Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer. International Journal of Nanomedicine 4: 99–105.PubMedCentralPubMedGoogle Scholar
  25. Murakami, M., M.J. Ernsting, E. Undzys, N. Holwell, W.D. Foltz, and S.D. Li. 2013. Docetaxel conjugate nanoparticles that target alpha-smooth muscle actin-expressing stromal cells suppress breast cancer metastasis. Cancer Research 73: 4862–4871.PubMedCrossRefGoogle Scholar
  26. Nyman, D.W., K.J. Campbell, E. Hersh, K. Long, K. Richardson, V. Trieu, N. Desai, M.J. Hawkins, and D.D. Von Hoff. 2005. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. Journal of Clinical Oncology 23: 7785–7793.PubMedCrossRefGoogle Scholar
  27. Opanasopit, P., M. Yokoyama, M. Watanabe, K. Kawano, Y. Maitani, and T. Okano. 2005. Influence of serum and albumins from different species on stability of camptothecin-loaded micelles. Journal of Controlled Release 104: 313–321.PubMedCrossRefGoogle Scholar
  28. Savić, R., T. Azzam, A. Eisenberg, and D. Maysinger. 2006. Assessment of the integrity of poly(caprolactone)-b-poly(ethylene oxide) micelles under biological conditions: A fluorogenic-based approach. Langmuir 22: 3570–3578.PubMedCrossRefGoogle Scholar
  29. Sherwood, L. 2011. Human physiology: From cells to systems. Belmont, CA: Cengage Learning.Google Scholar
  30. Sun, Q., M. Radosz, and Y. Shen. 2012. Challenges in design of translational nanocarriers. Journal of Controlled Release 164: 156–169.PubMedCrossRefGoogle Scholar
  31. Xu, P., E. Gullotti, L. Tong, C.B. Highley, D.R. Errabelli, T. Hasan, J.-X. Cheng, D.S. Kohane, and Y. Yeo. 2009. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Molecular Pharmaceutics 6: 190–201.PubMedCentralPubMedCrossRefGoogle Scholar
  32. Zhou, Z., Y. Shen, J. Tang, M. Fan, E.A. Van Kirk, W.J. Murdoch, and M. Radosz. 2009. Charge-reversal drug conjugate for targeted cancer cell nuclear drug delivery. Advanced Functional Materials 19: 3580–3589.CrossRefGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2013

Authors and Affiliations

  1. 1.Weldon School of Biomedical EngineeringPurdue UniversityWest LafayetteUSA
  2. 2.Department of Industrial and Physical PharmacyPurdue UniversityWest LafayetteUSA
  3. 3.Biomedical Research InstituteKorea Institute of Science and TechnologySeoulRepublic of Korea

Personalised recommendations